GlassScriptPhysician profile
Tamela L Charbonnet
NPI 1215934401
$25,656.74
in general payments reported to CMS, 2019-2025
42 companies · $4,497 in 2025
The $4,497 reported for 2025 was more than what 89% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,383 · 2020: $2,197 · 2021: $3,571 · 2022: $4,830 · 2023: $4,368 · 2024: $3,811 · 2025: $4,497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $487.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,189.22 |
| Education | $487.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,638.98 | 2019-2025 | Skyrizi, Rinvoq, Botox |
| Janssen Biotech, INC. | $2,069.25 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Sun Pharmaceutical Industries INC. | $1,975.37 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Novartis Pharmaceuticals Corporation | $1,912.04 | 2019-2025 | |
| Genzyme Corporation | $1,721.49 | 2019-2025 | |
| Pfizer INC. | $1,697.87 | 2019-2025 | |
| Lilly USA, LLC | $1,678.27 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Regeneron Healthcare Solutions, INC. | $1,393.86 | 2019-2025 | Dupixent, Libtayo |
| Ucb, INC. | $1,058.58 | 2019-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $1,013.78 | 2022-2025 | Sotyktu |
| Leo Pharma INC. | $1,007.48 | 2019-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $633.04 | 2019-2025 | Nemluvio, Aklief |
| Amgen INC. | $610.80 | 2019-2025 | Otezla, Otezla |
| Incyte Corporation | $514.67 | 2021-2025 | Opzelura |
| Almirall LLC | $460.78 | 2019-2025 | Seysara, Klisyri |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $447.74 | 2023-2025 | Zoryve |
| Mayne Pharma Commercial LLC | $434.17 | 2019-2025 | |
| Genentech USA, INC. | $335.58 | 2019-2022 | |
| Dermavant Sciences, INC. | $331.16 | 2023-2024 | Vtama |
| Sanofi-Aventis U.S. LLC | $254.76 | 2020-2022 | |
| Medimetriks Pharmaceuticals, INC. | $224.87 | 2019-2025 | Genadur, Neo-Synalar |
| Biofrontera INC. | $206.12 | 2019-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Hill Dermaceuticals, INC. | $145.40 | 2023-2024 | Tolak |
| Journey Medical Corporation | $127.79 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.80 | 2023-2024 | Spevigo, Cyltezo |
| Organon LLC | $96.62 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $89.08 | 2019-2022 | |
| Verrica Pharmaceuticals INC. | $83.15 | 2023-2024 | Ycanth |
| Botanix Sb INC | $56.93 | 2025 | Sofdra |
| Elekta, INC. | $47.02 | 2025 | Flexitron Hdr |
| Vyne Pharmaceuticals INC. | $46.12 | 2020-2021 | |
| Sandoz INC. | $39.86 | 2023 | Hyrimoz |
| Revance Therapeutics, INC. | $37.03 | 2024 | Daxxify |
| Ani Pharmaceuticals, INC. | $33.06 | 2023 | Apexicon E |
| Celgene Corporation | $26.61 | 2019 | |
| Krystal Biotech INC | $21.02 | 2025 | Vyjuvek |
| Dermira, INC. | $19.88 | 2020 | |
| Helsinn Therapeutics (U.S.), INC. | $15.37 | 2023 | Valchlor |
| Pierre Fabre Pharmaceuticals, INC. | $13.50 | 2019 | |
| Icad, INC | $13.40 | 2023 | Axxent Surface Controller |
| Sebela Pharmaceuticals INC. | $12.95 | 2020 | |
| Epi Health, LLC | $9.49 | 2019-2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamela Charbonnet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.